Jessica Tassan
Stock Analyst at Piper Sandler
(0.97)
# 3,950
Out of 5,152 analysts
86
Total ratings
27.4%
Success rate
-15.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $281.27 | +31.55% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $5.12 | +75.78% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $26.07 | +61.10% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $42.26 | +15.95% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $45.84 | +30.89% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $18.61 | +61.25% | 6 | Jan 6, 2026 | |
| CVS CVS Health | Reiterates: Overweight | $99 → $101 | $78.69 | +28.35% | 6 | Dec 10, 2025 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $14.39 | +73.73% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $288.77 | +44.41% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $12.08 | +181.46% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $3.40 | +429.41% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.93 | +107.25% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $17.50 | +391.43% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $180.75 | +50.48% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $5.60 | +42.86% | 3 | May 23, 2025 |
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $281.27
Upside: +31.55%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $5.12
Upside: +75.78%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $26.07
Upside: +61.10%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $42.26
Upside: +15.95%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $45.84
Upside: +30.89%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $18.61
Upside: +61.25%
CVS Health
Dec 10, 2025
Reiterates: Overweight
Price Target: $99 → $101
Current: $78.69
Upside: +28.35%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $14.39
Upside: +73.73%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $288.77
Upside: +44.41%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $12.08
Upside: +181.46%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $3.40
Upside: +429.41%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.93
Upside: +107.25%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $17.50
Upside: +391.43%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $180.75
Upside: +50.48%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $5.60
Upside: +42.86%